PMID- 36875472
OWN - NLM
STAT- MEDLINE
DCOM- 20230308
LR  - 20230314
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Probiotics intervention in preventing conversion of impaired glucose tolerance to 
      diabetes: The PPDP follow-on study.
PG  - 1113611
LID - 10.3389/fendo.2023.1113611 [doi]
LID - 1113611
AB  - OBJECTIVES: The purpose of this study was to assess the incidence of type 2 
      diabetes mellitus (T2DM) after 6 years in patients with IGT who received early 
      probiotic intervention in the Probiotics Prevention Diabetes Program (PPDP) 
      trial. METHODS: 77 patients with IGT in the PPDP trial were randomized to either 
      probiotic or placebo. After the completion of the trial, 39 non-T2DM patients 
      were invited to follow up glucose metabolism after the next 4 years. The 
      incidence of T2DM in each group was assessed using Kaplan-Meier analysis. The 16S 
      rDNA sequencing technology was used to analyze gut microbiota's structural 
      composition and abundance changes between the groups. RESULTS: The cumulative 
      incidence of T2DM was 59.1% with probiotic treatment versus 54.5% with placebo 
      within 6 years, there was no significant difference in the risk of developing 
      T2DM between the two groups (P=0.674). CONCLUSIONS: Supplemental probiotic 
      therapy does not reduce the risk of IGT conversion to T2DM. CLINICAL TRIAL 
      REGISTRATION: https://www.chictr.org.cn/showproj.aspx?proj=5543, identifier 
      ChiCTR-TRC-13004024.
CI  - Copyright (c) 2023 Yan, Hu, Tian, Li, Yu, Li and Feng.
FAU - Yan, Qun
AU  - Yan Q
AD  - Department of Endocrinology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Hu, Weiting
AU  - Hu W
AD  - The Second Clinical Medical College, Shanxi Medical University, Second Hospital 
      of Shanxi Medical University, Taiyuan, China.
FAU - Tian, Yan
AU  - Tian Y
AD  - Department of Endocrinology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Li, Xu
AU  - Li X
AD  - Department of Endocrinology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Yu, Yuan
AU  - Yu Y
AD  - Department of Endocrinology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Li, Xing
AU  - Li X
AD  - The Second Clinical Medical College, Shanxi Medical University, Second Hospital 
      of Shanxi Medical University, Taiyuan, China.
FAU - Feng, Bo
AU  - Feng B
AD  - Department of Endocrinology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
LA  - eng
SI  - ChiCTR/ChiCTR-TRC-13004024
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230217
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/prevention & control
MH  - *Glucose Intolerance
MH  - Kaplan-Meier Estimate
MH  - *Probiotics/therapeutic use
PMC - PMC9982119
OTO - NOTNLM
OT  - conversion
OT  - diabetes mellitus
OT  - gut microbiota
OT  - impaired glucose tolerance
OT  - probiotic
OT  - type 2
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/03/07 06:00
MHDA- 2023/03/08 06:00
PMCR- 2023/01/01
CRDT- 2023/03/06 04:10
PHST- 2022/12/01 00:00 [received]
PHST- 2023/02/07 00:00 [accepted]
PHST- 2023/03/06 04:10 [entrez]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/08 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1113611 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Feb 17;14:1113611. doi: 
      10.3389/fendo.2023.1113611. eCollection 2023.